EBS Stock Overview
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs).
Emergent BioSolutions Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$46.97|
|52 Week High||US$127.20|
|52 Week Low||US$29.88|
|1 Month Change||3.19%|
|3 Month Change||-7.65%|
|1 Year Change||-56.15%|
|3 Year Change||-21.74%|
|5 Year Change||55.79%|
|Change since IPO||301.45%|
Recent News & Updates
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Emergent BioSolutions: Rapid-Return Trade With More Legs
The modification/loss of a contract coupled with a weak earnings report sent the stock tumbling 40%. We jumped on this overreaction for a quick gain, but now see the stock rallying further into 2022 on some bullish developments. The company is anticipating a significant top-line ramp up in 2023 and 2024.
|EBS||US Biotechs||US Market|
Return vs Industry: EBS underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: EBS underperformed the US Market which returned 4.2% over the past year.
|EBS Average Weekly Movement||13.2%|
|Biotechs Industry Average Movement||10.2%|
|Market Average Movement||6.7%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: EBS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: EBS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company’s products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine.
Emergent BioSolutions Fundamentals Summary
|EBS fundamental statistics|
Is EBS overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EBS income statement (TTM)|
|Cost of Revenue||US$913.50m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||4.22|
|Net Profit Margin||13.74%|
How did EBS perform over the long term?See historical performance and comparison
Is Emergent BioSolutions undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EBS ($46.97) is trading below our estimate of fair value ($78.04)
Significantly Below Fair Value: EBS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EBS is good value based on its PE Ratio (11.1x) compared to the US Biotechs industry average (23.1x).
PE vs Market: EBS is good value based on its PE Ratio (11.1x) compared to the US market (16.5x).
Price to Earnings Growth Ratio
PEG Ratio: EBS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: EBS is good value based on its PB Ratio (1.7x) compared to the US Biotechs industry average (1.9x).
How is Emergent BioSolutions forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EBS's earnings are forecast to decline over the next 3 years (-4.5% per year).
Earnings vs Market: EBS's earnings are forecast to decline over the next 3 years (-4.5% per year).
High Growth Earnings: EBS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: EBS's revenue is expected to decline over the next 3 years (-7.4% per year).
High Growth Revenue: EBS's revenue is forecast to decline over the next 3 years (-7.4% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EBS's Return on Equity is forecast to be high in 3 years time
How has Emergent BioSolutions performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EBS has high quality earnings.
Growing Profit Margin: EBS's current net profit margins (13.7%) are higher than last year (12.5%).
Past Earnings Growth Analysis
Earnings Trend: EBS's earnings have grown significantly by 36.7% per year over the past 5 years.
Accelerating Growth: EBS's earnings growth over the past year (36.3%) is below its 5-year average (36.7% per year).
Earnings vs Industry: EBS earnings growth over the past year (36.3%) exceeded the Biotechs industry 11%.
Return on Equity
High ROE: EBS's Return on Equity (14.9%) is considered low.
How is Emergent BioSolutions's financial position?
Financial Position Analysis
Short Term Liabilities: EBS's short term assets ($1.1B) exceed its short term liabilities ($365.4M).
Long Term Liabilities: EBS's short term assets ($1.1B) exceed its long term liabilities ($979.4M).
Debt to Equity History and Analysis
Debt Level: EBS's net debt to equity ratio (29.9%) is considered satisfactory.
Reducing Debt: EBS's debt to equity ratio has increased from 48.9% to 56.4% over the past 5 years.
Debt Coverage: EBS's debt is well covered by operating cash flow (27.6%).
Interest Coverage: EBS's interest payments on its debt are well covered by EBIT (9.8x coverage).
What is Emergent BioSolutions's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate EBS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EBS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EBS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EBS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EBS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Bob Kramer (64 yo)
Mr. Robert G. Kramer., also known as Bob, has been President at Emergent BioSolutions Inc. since March 26, 2018 and has been its Chief Executive Officer and Director since April 01, 2019. Mr. Kramer was Ch...
CEO Compensation Analysis
Compensation vs Market: Bob's total compensation ($USD5.57M) is about average for companies of similar size in the US market ($USD5.29M).
Compensation vs Earnings: Bob's compensation has increased by more than 20% in the past year.
Experienced Management: EBS's management team is considered experienced (3.8 years average tenure).
Experienced Board: EBS's board of directors are considered experienced (8.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: EBS insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Emergent BioSolutions Inc.'s employee growth, exchange listings and data sources
- Name: Emergent BioSolutions Inc.
- Ticker: EBS
- Exchange: NYSE
- Founded: 1998
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$2.527b
- Shares outstanding: 53.80m
- Website: https://www.emergentbiosolutions.com
Number of Employees
- Emergent BioSolutions Inc.
- 400 Professional Drive
- Suite 400
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/23 23:08|
|End of Day Share Price||2022/01/21 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.